Month: September 2025

Lumotive secured $45 million to expand sales of its programmable optical semiconductors, aiming to bring its light-shaping technology from the lab into AI data centers, autonomous systems, and other emerging markets.

DANNCE.AI is launching an AI-powered, video-based biomarker platform designed to help clinicians and drug developers better characterize drug effects, optimize neurological care, and bring more precision and objectivity to movement disorder diagnosis and monitoring.

Academic innovators from across the Triangle participated in a three-day, hands-on workshop led by Duke, NC State, and UNC—learning how to launch life-science startups in FDA-regulated markets.

Over its first decade, Duke Capital Partners built a $105 million portfolio backing more than 60 startups—now collectively valued at over $10 billion—fueling alumni-led innovation with real impact.

Uplizna became the first-ever FDA-approved treatment for IgG4-related disease—cutting flare risk by 87% and offering a long-sought therapy for this rare immune condition.

Sparta Biomedical treated the first patients with Ormi—a breakthrough synthetic cartilage implant using the Galene platform—in its inaugural human trial targeting focal knee lesions.

Humacyte obtained FDA approval for Symvess—an off-the-shelf, acellular engineered vessel—for urgent repair of limb-threatening arterial injuries when autologous veins aren’t an option.

Tune Therapeutics closed a $175M Series B to advance its epigenome-editing pipeline, including a clinical-stage program for chronic hepatitis B.

Basking Biosciences dosed the first patients in its Phase 2 trial of BB-031, a reversible RNA aptamer designed to safely treat acute ischemic stroke.